Edwards Lifesciences Corporation provided earnings guidance for the second quarter and full year of 2022. For the quarter, the company expects total sales to be between $1.36 billion to $1.44 billion.

For the full year, the company expects sales to grow at a low double-digit underlying rate to be between $5.5 billion to $6.0 billion, which includes an estimated negative year-over-year impact of $170 million from foreign exchange.